AngioDynamics Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended November 30, 2018; Reiterates Earnings Guidance for the Fiscal Year 2019
January 04, 2019 at 06:44 pm IST
Share
AngioDynamics Inc. announced unaudited consolidated earnings results for the second quarter and six months ended November 30, 2018. For the quarter, the company's net sales were $91,503,000 against $86,706,000 a year ago. Operating income was $3,981,000 against $1,123,000 a year ago. Net income was $2,140,000 against $249,000 a year ago. Earnings per basic and diluted share were $0.06 against $0.01 a year ago. Adjusted diluted EPS was $0.22 against $0.17 a year ago.
For the six months, the company's net sales were $176,843,000 against $172,117,000 a year ago. Operating income was $4,307,000 against $1,263,000 a year ago. Net income was $1,671,000 against $214,000 a year ago. Earnings per basic and diluted share were $0.04 against $0.01 a year ago. Adjusted diluted EPS was $0.38 against $0.30 a year ago.
For the fiscal year 2019, the Company reiterates its financial guidance, continuing to expect net sales in the range of $354 million to $359 million. Additionally, the Company continues to expect adjusted earnings per share in the range of $0.82 to $0.86.
AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. Its product categories include oncology, venous therapies, vascular interventions, and ports. Its oncology products include Model 1500X RF Generator, IsoLoc Endorectal Balloon, Habib 4X Laparoscopic Bipolar Resection Device, Habib 4X Bipolar Resection Device, and Alatus. Its venous therapies include VenaCure EVLT 1470 Pro Laser, VenaCure EVLT System, VenaCure EVLT Procedure Packs, and others.
AngioDynamics Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended November 30, 2018; Reiterates Earnings Guidance for the Fiscal Year 2019